Fat metabolism research fragment
AOD-9604.
5 vendors · €21–60
Modified C-terminal fragment of human growth hormone (hGH 177–191). Researched for adipose-tissue mechanisms; not approved for human therapeutic use.
Live vendor register · grouped by strength
Every vendor. Cheapest per mg first, kits listed separately.
AOD-9604 · price per mg
5 listings · unflagged vendors first · Listings data last updated October 2026
Best price per mg: Pepsup 5 mg at €7.00/mg.
2 mg
1 listing01
Direct Peptides EUVID-DIRECT-P · UK network · from £18.33
2 mg
99%
HPLC badge only (no reports published)
In stock
10–14 days
€10.50/mg
€21
5 mg
3 listings01
PepsupVID-PEPSUP · NL dispatch · €34.99
5 mg
99%
No COA published (mfr claim 99%+)
In stock
NL 1–2 d · EU 2–5 d
€7.00/mg
€35
02
Particle PeptidesVID-PARTICLE · SK dispatch
5 mg
99.8%
Liquilabs (CZ) · batch 2025256, published 2025-08-13 · HPLC · FTIR · microbial counts · endotoxin · elemental impurities · purity >99.8% · no MS identity on this reportLiquilabs · HPLC · FTIR · TAMC/TYMC · LAL · Elemental impurities · Batch 2025256 · Aug 13, 2025
In stock
2–7 days
€9.00/mg
€45
03
Adria ScienceVID-ADRIA-SC · SI/CZ dispatch
5 mg
99.2%
Liquilabs per-lot COA · USP<85>
In stock
Dispatch 1–3 days
€12.00/mg
€60
Flagged vendors · documented, never recommended
01
CertaPeptidesVID-CERTAPEP · RO dispatch
5 mg
98%
Janoshik (selected lots)
In stock
3–7 days
€14.00/mg
€70
Same research area
Similar compounds.
GH secretagogue research
Ipamorelin
Synthetic pentapeptide described in 1998 by Novo Nordisk researchers as a selective ghrelin/GH-secretagogue receptor agonist; researched for growth-hormone release. Not approved for human therapeutic use.
7 vendors€14–45
GHRH analogue research
CJC-1295
GHRH(1-29) analogue developed by ConjuChem; the DAC form binds albumin and persists for days, the no-DAC form (Mod GRF 1-29) is short-acting. Researched for GH/IGF-1 stimulation; not approved for human therapeutic use.
7 vendors€22–89
Triple hormone agonist research
Retatrutide
Investigational triple GIP/GLP-1/glucagon receptor agonist (LY3437943) developed by Eli Lilly and studied in Phase 3 trials; not approved as a medicine anywhere and not for human therapeutic use.
5 vendors€70–122
GIP/GLP-1 dual agonist research
Tirzepatide
Dual GIP/GLP-1 receptor agonist, FDA- and EMA-approved as Mounjaro and Zepbound. Research-vial tirzepatide is a different, unapproved product, not made or reviewed as those medicines, and not for human use.
3 vendors€40–90
Amylin analogue research
Cagrilintide
Long-acting amylin-receptor agonist (AM833 / NNC0174-0833) developed by Novo Nordisk, studied alone and in the CagriSema combination; not approved as a medicine anywhere and not for human therapeutic use.
1 vendor€103
Long-form research guide
Weight Loss Research. Mechanism + protocols + safety.
Lipolysis, GH secretagogues, and adipose tissue modulation in obesity models
Open the long-form guide for AOD-9604 →